OncoGenex Pharmaceuticals, Inc. (OGXI) Posts Q4 Loss of 98c/Share

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) reported Q4 EPS of ($0.98), $0.37 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.86 million.

For earnings history and earnings-related data on OncoGenex Pharmaceuticals, Inc. (OGXI) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c